CPRX Q4 2021 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+23.5% YoY

Gross Profit

$31M80.8% margin

Operating Income

$13M33.3% margin

Net Income

$9M24.3% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

+6.6%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$19M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$238M

Total Liabilities

$31M

Stockholders' Equity

$207M

Cash & Equivalents

$171M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$31M	+23.5%
Gross Profit	$31M	$26M	+18.4%
Operating Income	$13M	$9M	+47.9%
Net Income	$9M	$11M	-18.6%

Revenue Segments

Product Revenue Net

$38M100%